Amgen, Allergan submit application for biosimilar bevacizumab

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AMGEN and ALLERGAN plc. have submitted a Biologics License Application to FDA for ABP 215, a biosimilar candidate to Avastin (bevacizumab). ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on. The companies said they believe this submission is the first bevacizumab biosimilar application submitted to FDA.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login